Rigel Pharmaceuticals, Inc. (RIGL)

US — Healthcare Sector
Peers: FBIO  RVPH  CTIC  OCUP  NBRV  EIGR  PIRS  CDTX  XFOR  MREO  INZY  TERN  LPTX  ZURA  ENVB  EFTR  IMMX  ELEV  DAWN  ABOS  VECT 

Automate Your Wheel Strategy on RIGL

With Tiblio's Option Bot, you can configure your own wheel strategy including RIGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RIGL
  • Rev/Share 11.4037
  • Book/Share 1.0426
  • PB 19.5565
  • Debt/Equity 3.289
  • CurrentRatio 2.1997
  • ROIC 0.3438

 

  • MktCap 364418236.0
  • FreeCF/Share 2.0043
  • PFCF 10.2098
  • PE 9.7667
  • Debt/Assets 0.347
  • DivYield 0
  • ROE -6.5526

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?
RIGL
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?
RIGL
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
RIGL
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress.

Read More
image for news Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now
RIGL
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel (RIGL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Read More
image for news Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now
Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?
RIGL
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?
Earnings Estimates Rising for Rigel (RIGL): Will It Gain?
RIGL
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Read More
image for news Earnings Estimates Rising for Rigel (RIGL): Will It Gain?
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet
RIGL
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum
RIGL
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive

Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments. R289's promising pipeline progress and TAVALISSE's patent extension to 2032 bolster Rigel's long-term outlook, despite reliance on key products and competitive markets.

Read More
image for news Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript
RIGL
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Kalpit Patel - B.

Read More
image for news Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates
RIGL
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to loss of $0.50 per share a year ago.

Read More
image for news Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates
Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock?
RIGL
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock?
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
BVS, ENSG, FOLD, RIGL
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

Read More
image for news 4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade
RIGL
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade
Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates
RIGL
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to break-even earnings per share a year ago.

Read More
image for news Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
RIGL
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.

Read More
image for news Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
RIGL
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.

Read More
image for news RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?

About Rigel Pharmaceuticals, Inc. (RIGL)

  • IPO Date 2000-11-29
  • Website https://www.rigel.com
  • Industry Biotechnology
  • CEO Mr. Raul R. Rodriguez
  • Employees 162

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.